Boehringer Ingelheim Ltd, Berkshire, UK.
Eli Lilly and Company, Basingstoke, UK.
Clin Ther. 2018 Jan;40(1):152-154. doi: 10.1016/j.clinthera.2017.11.009. Epub 2017 Dec 13.
Members of the dipeptidyl peptidase-4 inhibitor drug class are indicated for glycemic control in patients with type 2 diabetes mellitus and all, except linagliptin, require dose adjustment in renal impairment. A cross-sectional analysis of a cohort of type 2 diabetes mellitus patients treated with dipeptidyl peptidase-4 inhibitors identified in the Clinical Practice Research Datalink was conducted to explore compliance with the renal adjustment requirements of the Summaries of Product Characteristics. Approximately one third of type 2 diabetes mellitus patients with creatinine clearance <50 mL/min who were at risk of inappropriate prescribing, were initiated on a DPP-4 inhibitor at a higher dose than the specified in their respective Summary of Product Characteristics.
二肽基肽酶-4 抑制剂类药物适用于 2 型糖尿病患者的血糖控制，除了利拉利汀外，所有药物在肾功能损害时都需要调整剂量。通过对临床实践研究数据库中发现的二肽基肽酶-4 抑制剂治疗的 2 型糖尿病患者队列进行横断面分析，探讨了对产品特性摘要中肾功能调整要求的遵守情况。大约三分之一的肾小球滤过率<50 mL/min 的 2 型糖尿病患者存在不适当处方的风险，他们开始使用的二肽基肽酶-4 抑制剂剂量高于各自产品特性摘要中规定的剂量。
